Translating Pre-Clinical Research to Clinical Patient Care™
JMSACL |
Editorial Structure
Associate Editors : JMSACL
|
 |
Data Science | |
 | Dustin Bunch, PhD, DABCC Nationwide Children's Hospital, Columbus, Ohio, United States  Data Science Machine Learning TDM Metabolomics Small Molecules Clinical Implementation Method Development & Validation Dustin R. Bunch, is an Asst. Director of Clinical Chemistry & Co-Director Laboratory Informatics at Nationwide Children's Hospital. His research focuses small molecule analysis by mass spectrometry in a clinical setting and clinical informatics. He completed his Clinical Chemistry Fellowship at Yale-New Haven Hospital where he was able to expand his data science abilities. Prior to his fellowship, he spent 10 years at the Cleveland Clinic as a research and development scientist for clinical mass spectrometry. |
 | Randall Julian, PhD Indigo BioAutomation, Carmel, Indiana, United States Data Science Machine Learning Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to analyze data from laboratories across the US automatically. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue. |
Endocrinology | |
 | Giorgia Antonelli, PhD University of Padova, Padova, Italy Endocrinology Clinical Implementation Method Development & Validation Sample Prep Steroids Giorgia graduated in 2004 with a masters degree in Pharmaceuticals Technology and Chemistry from the University of Padova (Italy). In 2008, she finished her PhD in Cellular and Molecular Pharmacology. In 2018 she obtained the National Academic qualification as Associate Professor in Clinical Biochemistry and Clinical Molecular Biology. Following her first experience in a research laboratory in 2011, she has since worked in a clinical laboratory on LC-MS/MS method validation, in particular for endocrinology applications. Her skills also include ISO15189 accreditation, especially for method verification and validation. |
 | Daniel Holmes, MD, FRCPC St. Paul’s Hospital, Vancouver, British Columbia, Canada 
Endocrinology Data Science Small Molecules Automation Sample Prep Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine. |
 | Mark Kushnir, PhD ARUP Institute for Clinical & Experimental Pathology, Salt Lake City, Utah, United States
Endocrinology Proteomics Small Molecules Biomarkers Method Development & Validation Sample Prep Quantitative MS Clinical Implementation Mark Kushnir is Scientific Director, Mass Spectrometry R&D at ARUP Institute for Clinical and Experimental Pathology and Adjunct Assistant Professor at the Department of Pathology, University of Utah School of Medicine. He received PhD in Analytical Chemistry from Uppsala University (Uppsala, Sweden); his main areas of interest include development, application and clinical evaluation of novel mass spectrometry based clinical diagnostic methods for small molecule, protein and peptide biomarkers. He is author/coauthor of over 100 scientific peer reviewed publications. |
 | Mirko Peitzsch, PhD University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany Endocrinology Small Molecules Steroids Metabolite Role and Activity Mirko is working at the Institute for Clinical Chemistry and Laboratory Medicine (IKL) of the University Hospital Carl Gustav Carus Dresden, where as the head of the Experimental Mass Spectrometry unit, he is responsible for the development and application of LC-MS/MS based targeted and untargeted analysis. One focus in recent years has been the clinical application of LC-MS/MS based methods for determining adrenal hormones for diagnosis of various causes of secondary hypertension. |
Glycomics | |
Imaging | |
 | Jörg Hanrieder, PhD Sahlgrenska Hospital - University of Gothenburg, Gothenburg, Sweden Imaging Clinical Implementation Biomarkers Proteomics Peptidomics Lipidomics I have a background in Chemistry (MS, Univ Leipzig, Germany) and a PhD in Neurochemistry (Uppsala Univ., Sweden). Currently, I am a group leader in Neurochemistry at Sahlgrenska Hospital - University of Gothenburg (Sweden) and the Institute of Neurology, UCL (UK). My background bridges key elements of analytical sciences with molecular neuroscience. In my lab, we employ state of the art mass spectrometry tools to understand key pathogenic mechanism of neurodegenerative diseases with the central aim to translate the outcomes of our research to applications critical in clinical neurology. |
 | Wojciech Michno, PhD Stanford University / University College London, Stanford, California, United States Imaging Proteomics Lipidomics Metabolomics Pathology Data Science Clinical Implementation During my PhD I worked with development and implementation of multimodal mass spectrometry approaches for analysis of neurodegenerative diseases, particularly Alzheimer’s disease, using animal and human subjects. My recent work focuses on cell-type specific multiomic analysis of brain development and disease, using human-derived in vitro organoids as a platform for clinical target identification (biomarkers) and treatment screening. |
 | Nicole Strittmatter, PhD Technical University of Munich, Munich, Germany Imaging Ambient Ionization Metabolomics Direct Infusion Microbiology I studied chemistry at the Justus-Liebig University in Giessen, specialising in Analytical Chemistry and Mass Spectrometry Applications. I subsequently performed my PhD studies with Prof Takats at Imperial College London (2012-2015), developing direct on sample applications for the characterisation and identification of microorganisms such as bacteria, fungi and mammalian cell lines. I joined AstraZeneca as a mass spectrometry imaging scientist in 2015, performing small molecule DESI and MALDI imaging as well as imaging mass cytometry studies to understand drug disposition, drug efficacy and safety and for systems-level tumour model characterisation studies. Expertise: Direct infusion MS techniques, MS imaging, metabolomics, ambient MS. |
Instrumentation | |
 | Christopher Chouinard, PhD Clemson University, Melbourne, Florida, United States
Instrumentation Steroids Ion Mobility I received my PhD from University of Florida in 2016, where I developed ion mobility-mass spectrometry (IM-MS) methods for steroids and vitamin D metabolites. I then worked as post-doctoral research at Pacific Northwest National Laboratory, building Structures for Loss Ion Manipulations (SLIM) ion mobility instrumentation for application in metabolomics and proteomics. Since 2018, I have been an Assistant Professor at Florida Institute of Technology. Work in my research group focuses on structurally selective reactions for improved characterization of steroids and other controlled substances with IM-MS. |
Lipidomics | |
 | Anne Bendt, PhD Singapore Lipidomics Incubator (SLING), National University of Singapore, Singapore
Lipidomics Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Associate Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization. |
 | Joshua Dubland, PhD The University of British Columbia & BC Children’s Hospital, Vancouver, British Columbia, Canada
Lipidomics Metabolomics Small Molecules Newborn Screening Biomarkers Clinical Implementation Josh is a Laboratory Scientist in the Newborn Screening and Biochemical Genetics Laboratories at BC Children's Hospital in Vancouver, Canada. He has a BSc in Chemistry from Simon Fraser University and a MSc in Chemistry from the University of Toronto. After working in the clinical and pharmaceutical industry for 4 years Josh returned to academia and completed a PhD in Experimental Medicine from the University of British Columbia with a focus on cardiovascular disease. Josh is passionate about developing and implementing innovative analytical strategies in the clinical laboratory with a focus on mass spectrometry. |
 | William Griffiths, PhD Swansea University, Swansea, Wales, United Kingdom Lipidomics Metabolomics Proteomics Endocrinology Steroids Small Molecules Imaging The Griffiths – Wang research group is focused on the mass spectrometric analysis of lipids and proteins. Current projects involve the study of cholesterol biosynthesis and metabolism, particularly the formation of oxysterols and bile acids. New and improved methods for the identification, quantification, and characterization of bile acids, oxysterols, and other sterols and steroids, are being developed; and the involvement of these molecules in neurogenesis and immunity is being investigated. Complementary to this, proteomic techniques are being used to study biosynthetic and metabolizing enzymes in tissues and cells. |
 | Robert Gurke, PhD Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany Lipidomics Metabolomics Biomarkers Clinical Implementation Method Development & Validation Robert Gurke received his diploma in chemistry at the Humboldt-University zu Berlin, Germany in 2012 followed by his doctoral thesis at the Technische Universität Dresden in 2016. After a short period as study director in a GLP-compliant bioanalytical company in Berlin he started working as research associate at the Institute of Clinical Pharmacology in Frankfurt under the guidance of Prof. Geisslinger. Mr Gurke is performing LC-MS/MS analysis since starting his doctoral thesis and gained broad experience in the field of developing and validating methods for the determination of exogenous and endogenous small molecules in different complex matrices. |
 | Tiffany Thomas, PhD Columbia University, New York City, New York, United States Lipidomics Metabolomics Small Molecules Fluxomics Method Development & Validation Dr. Thomas has over 20 years of mass spectrometry experience doing fluxomics, lipidomics, and metabolomics based experiments. She is the director of the New York Presbyterian Hospital/Columbia University Medical Center Biochemical Genetics Laboratory and is a Co-Director of the Laboratory of Transfusion Biology at Columbia University. She studies dietary factors of blood quality using high resolution mass spectrometry. |
Metabolomics | |
 | Dennis Bernieh, PhD University of Leicester, Leicester, United Kingdom Metabolomics TDM Microsampling Precision Medicine Dennis Bernieh is a Postdoctoral Researcher with the Cardiovascular Science department of the University of Leicester. He obtained his PhD in Applied Bioanalysis from De Montfort University. His research spans the application of novel bioanalytical technologies to solving challenging health problems particularly associated with the use of mass spectrometry for the bioanalysis of biomarkers, applying cutting edge precision medicine approaches to understand how fundamental metabolic processes are altered in cardiometabolic disease, identifying therapeutic targets for early diagnosis, prognosis, treatment optimisation, and clinical translation of findings from bench to bedside. |
Microbiology | |
Proteomics | |
 | David Barnidge, PhD The Binding Site, Rochester, Minnesota, United States Proteomics TDM Immunology Hematology Regulations & Standards David R. Barnidge, PhD, is a mass spectrometrist specializing in the development of new ways to analyze antibodies, also called immunoglobulins. Dr. Barnidge and pathologist David L. Murray, M.D., Ph.D., invented a new methodology called monoclonal immunoglobulin Rapid Accurate Molecular Mass (miRAMM), used to diagnose patients with B cell disorders by using mass spectrometry to measure the molecular weight of the antibodies secreted by B cells. This technology provides clinicians with an individualized picture of each patient's immune system, allowing them to treat patients more effectively. |
 | Pankaj Dwivedi, PhD Genentech, South San Francisco, California, United States Proteomics Data Science Pankaj has expertise in cancer biology, quantitative proteomics-phosphoproteomics, protein biochemistry, and proteomics data analysis. He has published seminal scientific papers on the cytokine receptor biology and its role in leukemia. His sphere of experience and interest includes but not limited to cell cultures, mouse models, processing proteomics samples and operating nano-LC-MS/MS. He has in-depth knowledge and understanding of quantitative proteomics techniques, e.g. SILAC, TMT, iTRAQ and RABA and understanding of aberrant proteomics as well as phospho-signaling and global ubiquitin profiles of solid and liquid tumor models. |
 | Theodora Katsila, PhD National Hellenic Research Foundation, Athens, Greece Proteomics Pharmacogenomics Toxicology Metabolomics Dr. Katsila did her undergraduate training in Biochemistry with a Year in Industry/Research at Imperial College London, UK and postgraduate studies in Clinical Biochemistry & Molecular Diagnostics at the National & Kapodistrian University of Athens, Greece. She received her PhD in Chemistry from the Biomedical Research Foundation Academy of Athens, Greece and University of Patras, Greece. After postdoctoral research at the University of Patras, Greece and close tights with industry, she joined Vall d’Hebron Institute of Oncology, Spain. Craving for brain teasers and driven by interdisciplinary approaches, her research interests span LC-MSn and translational biomarkers. Dr. Katsila is a Research Assistant Professor at the National Hellenic Research Foundation, Greece. |
 | Olgica Trenchevska, PhD Cowper Sciences, Chandler, Arizona, United States Proteomics MALDI PTMs I have obtained a degree as an Engineer in Chemistry focusing on analytical biochemistry, followed by a masters and PhD in Biochemistry (SS Cyril and Methodius University, N Macedonia) with a major focus on clinical proteomics and MALDI mass spectrometry. I have furthered my experience in a clinical laboratory (Clinic of Neurology), academia (The Biodesign Institute, ASU) and Industry (HealthTell Inc ). I am fascinated by mass spectrometry and the unambiguity it possess. I am currently a Senior Scientist at Cowper Sciences Inc, where I am focusing on exploring/applying novel methods and techniques in proteomics research, with potential for operation and commercialization. |
 | Yusheng Zhu, PhD, DABCC, FAACC Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States Proteomics Metabolomics Imaging Pathology Endocrinology Small Molecules TDM Toxicology Yusheng is Professor of Pathology and Pharmacology and Medical Director of Automated Testing Laboratory, Co-Director of Pathology Core Reference Laboratory, and Director of Postdoctoral Clinical Chemistry Training Program at Penn State University Hershey Medical Center. He is board certified by ABCC in Clinical Chemistry, Toxicological Chemistry, and Molecular Diagnostics and a Fellow of the AACC Academy. Currently, he is the Vice President of ABCC, Member of AACC Academy Council, Chair of AACC Academy Council Laboratory Utilization Task Force, and Chair of Mass Spectrometry & Separation Science Division. He is interested in research in clinical chemistry, toxicology, and clinical application of mass spectrometry. |
Regulations & Standards | |
Small Molecules | |
 | Liam Heaney, PhD Loughborough University, Loughborough, United Kingdom Small Molecules Toxicology Quantitative MS Biomarkers Metabolomics Breath Analysis Anti-Doping Dr Liam Heaney is a Lecturer in Bioanalytical Science at Loughborough University. His research interests include high-throughput measurement of small molecule biomarkers. This includes active projects that span across multiple disciplines including clinical diagnostic and prognostic applications and sports anti-doping/drugs of abuse. His work is centered around the application of analytical chemistry applying both gas chromatography and liquid chromatography-mass spectrometry. Prior to his current position, Liam spent time as a postdoctoral researcher at the University of Leicester’s NIHR Cardiovascular Biomedical Research Centre where he specialized in the analysis of cardiovascular disease biomarkers using MS-based techniques. |
 | Chia-Ni Lin, PhD Chang Gung Memorial Hospital, Taoyuan, Taiwan
Small Molecules Dr. Chia-Ni Lin is Associate Director in the Department of Laboratory Medicine at Chang Gung Memorial Hospital and Adjunct Assistant Professor at Chang Gung University. She received her Ph.D. degree in Clinical Laboratory Sciences and Medical Biotechnology from National Taiwan University followed by a fellowship in Clinical Chemistry at ARUP/University of Utah. She is board certificated by the American Board of Clinical Chemistry and a fellow of AACC academy. Her research interests are development, method improvement and validation of clinical laboratory assays, and mass spectrometry applications in clinical laboratory including metabolites in biological fluids, illicit drugs, trace elements and hormones. |
TDM | |
 | Jan-Willem Alffenaar, PhD, PharmD University of Sydney, Sydney, Australia
TDM Toxicology Infectious Disease Dried Blood Spots Transplant Medicine Point-of-Care Jan-Willem started his career in research during his residency in hospital pharmacy. After completion of his residency and PhD he remained involved in research. In addition to his clinical activities as hospital pharmacist in a tertiary care teaching hospital he was involved in several hospital activities. He was member of the antimicrobial drug committee and he chaired the PK/PD subcommittee. He served as hospital pharmacist as well as clinical pharmacologist the the Institutional Review Board evaluation medical research protocols. He also had a role in building a GCP certified framework for medical research in the hospital as co-chair of the drug trials committee. Internationally, he served on several committees on therapeutic drug monitoring in infectious diseases and alternative sampling strategies for therapeutic drug monitoring. Besides hosting several national and international symposia he has been frequently asked as invited speaker on international conferences, particularly in the field of tuberculosis and therapeutic drug monitoring. |
 | Peter Galettis, PhD University of Newcastle, Callaghan, New South Wales, Australia TDM Small Molecules Ambient Ionization Toxicology Instrumentation Dr Galettis currently holds the position of Head of the Clinical Pharmacology Laboratory at the University of Newcastle. He has previously held senior laboratory roles in academia, pathology and hospital settings where he was responsible for the development and implementation of new assays. Dr Galettis's research interests are entirely within the field of clinical pharmacology and toxicology, specialising in assay development for use in drug monitoring for the last 30 years, focussing on anticancer agents and drugs of abuse. |
 | Kamisha Johnson-Davis, PhD University of Utah and ARUP, Salt Lake City, Utah, United States TDM Toxicology Clinical Implementation Regulations & Standards Dr. Johnson-Davis is an Associate Professor (Clinical) at the University of Utah in the Department of Pathology and a Medical Director for Clinical Toxicology at ARUP Laboratories. She received her B.S. degree in Biochemistry from the University of California, Riverside and her Ph.D. in Pharmacology from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology and she completed a postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology. Dr. Johnson-Davis is board certified by the American Board of Clinical Chemistry in Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry and she is the Director for the Clinical Chemistry Fellowship Program at the University of Utah. |
Toxicology | |
 | Melissa Budelier, PhD TriCore Reference Laboratories Toxicology TDM Clinical Implementation Method Development & Validation Proteomics Small Molecules Biomarkers Diagnostics Dr. Budelier the Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification. |
 | Chi-Wei Lee, MD, PhD Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung City, Taiwan
Toxicology Ambient Ionization Method Development & Validation Clinical Implementation Dr. Lee received his M.D. and Ph.D. from the Kaohsiung Medical University in 1992 and 2016, respectively. With three specialty board certifications (viz. Internal Medicine, Emergency Medicine, Critical Care Medicine), he was in-charge-of the Emergency Department (Medical Division), Kaohsiung Medical University Hospital. As an Assistant Professor (Institute of Medical Science and Technology, National Sun Yat-Sen University), his research interest remains the development of efficacious techniques (both diagnostic and therapeutic) capable of improving the quality of patient care. For a decade, he has been focusing on the clinical applications of ambient mass spectrometry in the rapid identification of toxicants/toxins causing acute poisoning. |
 | Stephen Roper, PhD Washington University School of Medicine, St Louis, Missouri, United States Toxicology Glycoproteomics Small Molecules TDM Newborn Screening Proteomics My graduate studies centered on proteomic and glycoproteomic biomarker discovery in NSCLC. During this time, I gained experience with techniques such as Click chemistry and SILAC, as well as tissue imaging of N-linked glycans. In 2017 I completed a clinical chemistry postdoctoral fellowship where I focused on maternal and pediatric laboratory medicine, including the development and validation of HPLC and LC-MS/MS amino acid, adrenal steroid, and TDM assays. In 2017, I took a position at Washington University in St. Louis. Here, my work includes shared oversight of the clinical laboratory at St. Louis Children's Hospital and the toxicology section at Barnes Jewish Hospital. |
Join the conversation
© 2024 MSACL (a 501c3 Non-Profit California Corporation)